<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137382</url>
  </required_header>
  <id_info>
    <org_study_id>PANC3004</org_study_id>
    <secondary_id>2013-002819-10</secondary_id>
    <nct_id>NCT02137382</nct_id>
  </id_info>
  <brief_title>A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</brief_title>
  <official_title>A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion
      of fat, sugars and proteins) in Cystic Fibrosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of Fat Absorption (CFA)</measure>
    <time_frame>5 days</time_frame>
    <description>CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Nitrogen Absorption (CNA).</measure>
    <time_frame>5 days</time_frame>
    <description>CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fat Excretion</measure>
    <time_frame>5 days</time_frame>
    <description>Total amount of fat excreted during the stool collection period in grams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>5 days</time_frame>
    <description>Stool frequency is the average of the daily number of stools recorded during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With no Flatulence</measure>
    <time_frame>5 days</time_frame>
    <description>The percentage of days with no flatulence is calculated from the diary during the treatment period: 100*(number of days with no flatulence/number of days recorded in diary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With no Abdominal Pain</measure>
    <time_frame>5 days</time_frame>
    <description>The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100*(number of days with no abdominal pain/ number of days recorded in diary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Formed/Normal Stools</measure>
    <time_frame>5 days</time_frame>
    <description>The percentage of days with formed/normal stools is calculated from the diary during the treatment period: 100*(number of days with formed/normal stools/ number of days recorded in diary).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Creon N, then Creon®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to &lt;10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon® , then Creon N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to &lt;10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon®</intervention_name>
    <description>active comparator</description>
    <arm_group_label>Creon N, then Creon®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon N</intervention_name>
    <description>experimental drug</description>
    <arm_group_label>Creon® , then Creon N</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent given by the subject, or the parents, or a legally acceptable
             representative. If required by the Institutional Review Board/Ethics Committee
             (IRB/IEC), assent will be given by the subject

          -  Age ≥ 12 years

          -  Subjects who are able to swallow capsules with each meal and snacks

          -  Diagnosis of Cystic Fibrosis (CF) confirmed by two positive chloride sweat tests or
             gene analysis

          -  Diagnosis of pancreatic exocrine insufficiency proven by:

               1. Coefficient of fat absorption (CFA) &lt; 70% without supplementation

               2. or Human fecal elastase &lt; 50 μg/g stool

          -  Currently receiving treatment with a commercially available pancreatic enzyme product
             and on a continuous dose of this product for more than 3 months

          -  Clinically stable condition without evidence of acute respiratory disease within 1
             month of enrollment

          -  Stable body weight defined as no more than a 5% decline within 3 months of enrolment

          -  Females of child-bearing potential should agree to continue using a medically
             acceptable method of birth control throughout the study and for 30 days immediately
             after the last dose of study drug. Medically acceptable methods of birth control
             include bilateral tubal ligation or the use of either a contraceptive implant, a
             contraceptive injection (Depo-Provera™), an intrauterine device, or an oral
             contraceptive taken within the past 3 months where the subject agrees to continue
             using during the study or to adopt another birth control method, or a double-barrier
             method which consists of a combination of any two of the following: diaphragm,
             cervical cap, condom, or spermicide.

        Exclusion Criteria:

          -  Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic (except
             underlying disease), hematologic/immunologic, head, ears, eyes, nose, throat,
             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional (except
             underlying disease), endocrine (except diabetes mellitus), neurologic/psychiatric,
             allergy, recent major surgery, or other relevant diseases as revealed by history,
             physical examination and/or laboratory assessments, which could limit participation in
             or completion of the study

          -  History of acute abdomen

          -  History of fibrosing colonopathy

          -  History of distal intestinal obstruction syndrome (DIOS) within 6 months prior to
             enrollment

          -  Solid organ transplant or surgery affecting the large bowel other than appendectomy

          -  Small bowel surgery that significantly affected absorptive capacity (e.g. gastrectomy
             or pancreatectomy)

          -  Pregnancy or lactation

          -  Any type of malignancy involving the digestive tract in the last 5 years

          -  Celiac disease or Crohn's disease

          -  Known allergy to pancreatin or inactive ingredients (excipients) of pancreatin
             capsules

          -  Suspected non-compliance or non-cooperation

          -  Intake of experimental drugs within 30 days prior to study start

          -  Mental disability or any other lack of fitness, in the Investigator's opinion, to
             preclude subject's participation in or ability to complete the study

          -  Diagnosis of human immunodeficiency virus in medical history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje Sander-Struckmeier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research facility ID ORG-000826</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000816</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000827</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000825</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000829</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000828</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000815</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <results_first_submitted>September 18, 2015</results_first_submitted>
  <results_first_submitted_qc>October 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2015</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>50 patients consented, between January and March 2014.</recruitment_details>
      <pre_assignment_details>41 of the 50 patients who consented were randomized; the 9 patients who were not randomized were screening failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence: Creon N/Creon®</title>
          <description>Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to &lt;10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.</description>
        </group>
        <group group_id="P2">
          <title>Sequence: Creon®/Creon N</title>
          <description>Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to &lt;10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cross-over Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash Out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cross-over Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence Creon N/Creon® or Creon®/Creon N</title>
          <description>Participants who were randomized to receive either Creon N or Creon.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coefficient of Fat Absorption (CFA)</title>
        <description>CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon®: active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Fat Absorption (CFA)</title>
          <description>CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake</description>
          <population>Per protocol</population>
          <units>percentage of fat intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="9.23"/>
                    <measurement group_id="O2" value="89.5" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coefficient of Nitrogen Absorption (CNA).</title>
        <description>CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon®: active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Nitrogen Absorption (CNA).</title>
          <description>CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)</description>
          <population>Per protocol</population>
          <units>percentage of nitrogen intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" spread="5.47"/>
                    <measurement group_id="O2" value="87.8" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fat Excretion</title>
        <description>Total amount of fat excreted during the stool collection period in grams.</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon® : active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fat Excretion</title>
          <description>Total amount of fat excreted during the stool collection period in grams.</description>
          <population>Per protocol</population>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" spread="43.28"/>
                    <measurement group_id="O2" value="42.3" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency</title>
        <description>Stool frequency is the average of the daily number of stools recorded during the treatment period</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon®: active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>Stool frequency is the average of the daily number of stools recorded during the treatment period</description>
          <population>Per protocol</population>
          <units>number of stools per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.6"/>
                    <measurement group_id="O2" value="1.49" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With no Flatulence</title>
        <description>The percentage of days with no flatulence is calculated from the diary during the treatment period: 100*(number of days with no flatulence/number of days recorded in diary).</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon®: active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With no Flatulence</title>
          <description>The percentage of days with no flatulence is calculated from the diary during the treatment period: 100*(number of days with no flatulence/number of days recorded in diary).</description>
          <population>Per protocol</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" spread="46.65"/>
                    <measurement group_id="O2" value="57.5" spread="43.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With no Abdominal Pain</title>
        <description>The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100*(number of days with no abdominal pain/ number of days recorded in diary).</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon®: active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With no Abdominal Pain</title>
          <description>The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100*(number of days with no abdominal pain/ number of days recorded in diary).</description>
          <population>Per protocol</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="22.91"/>
                    <measurement group_id="O2" value="89.3" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Formed/Normal Stools</title>
        <description>The percentage of days with formed/normal stools is calculated from the diary during the treatment period: 100*(number of days with formed/normal stools/ number of days recorded in diary).</description>
        <time_frame>5 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Creon®</title>
            <description>Creon®: active comparator</description>
          </group>
          <group group_id="O2">
            <title>Creon N</title>
            <description>Creon N: experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Formed/Normal Stools</title>
          <description>The percentage of days with formed/normal stools is calculated from the diary during the treatment period: 100*(number of days with formed/normal stools/ number of days recorded in diary).</description>
          <population>Per protocol</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" spread="21.21"/>
                    <measurement group_id="O2" value="73.6" spread="29.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Creon®</title>
          <description>Creon®: active comparator</description>
        </group>
        <group group_id="E2">
          <title>Creon N</title>
          <description>Creon N: experimental drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastro intestinal hyper motility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Steatorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>viral rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gastric pH decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suntje Sander - Struckmeier</name_or_title>
      <organization>Abbott</organization>
      <phone>+49 (0) 511 6750 3254</phone>
      <email>suntje.sander-struckmeier@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

